Grm1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Gene Symbol |
GRM1 |
| Full Name |
Glutamate Metabotropic Receptor 1 |
| Chromosomal Location |
11q14.2 |
| NCBI Gene ID |
2917 |
| Ensembl ID |
ENSG00000168385 |
| UniProt ID |
Q9ULM0 |
| OMIM ID |
604473 |
| Protein Class |
G Protein-Coupled Receptor (Class C) |
| Species |
Human |
| Associated Diseases |
Spinocerebellar Ataxia, Autism, Schizophrenia, Parkinson's Disease, Cancer |
The GRM1 gene encodes metabotropic glutamate receptor 1 (mGluR1), a member of the group I metabotropic glutamate receptor family (along with GRM5). mGluR1 is a Gq-coupled receptor that plays critical roles in synaptic plasticity, learning, memory, and motor coordination. It is predominantly expressed in cerebellar Purkinje cells where it is essential for motor learning, and is also expressed in other brain regions including the hippocampus, basal ganglia, and cortex. GRM1 mutations cause spinocerebellar ataxia type 13 (SCA13), and dysregulated mGluR1 signaling is implicated in various neurological and psychiatric disorders.
mGluR1 is a class C GPCR that requires dimerization for function:
- Gq coupling: Activates phospholipase C (PLC) pathway
- IP3/DAG production: Leads to intracellular calcium release
- PKC activation: Modulates ion channel function
- ERK/MAPK signaling: Affects gene expression and plasticity
- Ion channel modulation: Modulates NMDA and AMPA receptors
Key characteristics:
- Dimeric structure: Forms homodimers or heterodimers with GRM5
- Cysteine-rich domain: Required for proper folding and trafficking
- Alternative splicing: Multiple splice variants (mGluR1a, mGluR1b, etc.)
- Long extracellular N-terminus: Contains the venus flytrap ligand-binding domain
- Highest: Cerebellum (Purkinje cells), olfactory bulb
- High expression: Hippocampus (CA1, CA3), basal ganglia, cerebral cortex
- Moderate expression: Thalamus, hypothalamus, brainstem
- Low expression: Most peripheral tissues
- Postsynaptic density: Primarily postsynaptic
- Excitatory synapses: On dendritic spines and shafts
- Presynaptic: Some presynaptic localization for autoreceptor function
- Disease-causing mutations: Over 20 GRM1 mutations identified
- Phenotype: Progressive cerebellar ataxia, dysarthria, cognitive impairment
- Mechanism: Loss-of-function leads to Purkinje cell dysfunction
- Therapeutic approaches: mGluR1 positive allosteric modulators (PAMs)
- Motor learning: mGluR1 in basal ganglia affects motor plasticity
- L-dopa-induced dyskinesias: mGluR1 antagonists may reduce dyskinesias
- Neuroprotection: mGluR1 activation may protect dopaminergic neurons
- Therapeutic target: mGluR1 PAMs under investigation
- Genetic associations: GRM1 variants linked to ASD
- Synaptic function: mGluR1 regulates synaptic plasticity relevant to ASD
- Therapeutic approaches: mGluR1 modulators under investigation
- Postmortem studies: Altered GRM1 expression in schizophrenia brains
- Therapeutic potential: mGluR1 modulators may address cognitive deficits
- Interaction with glutamate: Links to NMDA receptor hypofunction hypothesis
- Oncogenic role: GRM1 is aberrantly expressed in melanoma
- Metastasis: Promotes melanoma progression and metastasis
- Therapeutic target: mGluR1 antagonists for melanoma treatment
- No approved drugs: No selective mGluR1 modulators approved
- Research compounds: Multiple PAMs and NAMs in development
- Clinical trials: No active trials for neurological indications
| Compound |
Type |
Stage |
Notes |
| CHPG |
Agonist |
Research |
Low selectivity |
| JNJ16259685 |
Antagonist |
Research |
Brain-penetrant |
| ADX-10059 |
NAM |
Clinical |
Migraine trials |
| RG7203 |
PAM |
Preclinical |
Positive allosteric modulator |
- PAMs: Positive allosteric modulators for ataxia
- Neuroprotection: mGluR1 activation for PD
- Cognitive enhancement: mGluR1 modulation for cognition
- Cancer: mGluR1 antagonists for melanoma
- Cerebellar deficits: Severe ataxia, impaired motor learning
- Purkinje cell dysfunction: Abnormal dendritic morphology
- Learning deficits: Impaired cerebellar-dependent learning
- Compensatory mechanisms: Upregulation of other mGluRs
- SCA13 mutant mice for therapeutic testing
- Conditioned knockout for region-specific studies
- Reporter mice for expression studies
- Gene therapy: AAV-delivered GRM1 for SCA13
- Biomarkers: mGluR1 imaging ligands
- Personalized medicine: GRM1 genotyping for treatment
- Combination therapies: mGluR1 + other targets
The study of Grm1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:8265368 - Cloning of human GRM1
- PMID:14534151 - GRM1 and spinocerebellar ataxia
- PMID:15689453 - mGluR1 in Parkinson's disease
- PMID:16140868 - mGluR1 and synaptic plasticity
- PMID:19828788 - GRM1 in autism
- PMID:22842625 - mGluR1 in schizophrenia
- PMID:25057126 - GRM1 in melanoma
- PMID:29058363 - mGluR1 therapeutic potential